234 related articles for article (PubMed ID: 35451596)
21. Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge?
Brennan ET; Joy TR
Can J Cardiol; 2017 May; 33(5):666-673. PubMed ID: 28449837
[TBL] [Abstract][Full Text] [Related]
22. Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
Rosenson RS; Baker S; Banach M; Borow KM; Braun LT; Bruckert E; Brunham LR; Catapano AL; Elam MB; Mancini GBJ; Moriarty PM; Morris PB; Muntner P; Ray KK; Stroes ES; Taylor BA; Taylor VH; Watts GF; Thompson PD
J Am Coll Cardiol; 2017 Sep; 70(10):1290-1301. PubMed ID: 28859793
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
[TBL] [Abstract][Full Text] [Related]
24. Curcumin: An effective adjunct in patients with statin-associated muscle symptoms?
Sahebkar A; Saboni N; Pirro M; Banach M
J Cachexia Sarcopenia Muscle; 2017 Feb; 8(1):19-24. PubMed ID: 27897416
[TBL] [Abstract][Full Text] [Related]
25. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
26. Management of the patient with statin intolerance.
Vandenberg BF; Robinson J
Curr Atheroscler Rep; 2010 Jan; 12(1):48-57. PubMed ID: 20425271
[TBL] [Abstract][Full Text] [Related]
27. [Statin intolerance].
Graversen CB; Larsen ML; Schmidt EB
Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324293
[TBL] [Abstract][Full Text] [Related]
28. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
29. [Statin myopathy--rarity or reality?].
Pella D
Vnitr Lek; 2010 Sep; 56(9 Suppl):972-6. PubMed ID: 21137170
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.
Kennedy SP; Barnas GP; Schmidt MJ; Glisczinski MS; Paniagua AC
J Clin Lipidol; 2011; 5(4):308-15. PubMed ID: 21784377
[TBL] [Abstract][Full Text] [Related]
31. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
Koskinas K; Wilhelm M; Windecker S
Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
[TBL] [Abstract][Full Text] [Related]
32. SAMSON and the Nocebo Effect: Management of Statin Intolerance.
Krishnamurthy A; Bradley C; Ascunce R; Kim SM
Curr Cardiol Rep; 2022 Sep; 24(9):1101-1108. PubMed ID: 35759168
[TBL] [Abstract][Full Text] [Related]
33. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
Banach M; Rizzo M; Toth PP; Farnier M; Davidson MH; Al-Rasadi K; Aronow WS; Athyros V; Djuric DM; Ezhov MV; Greenfield RS; Hovingh GK; Kostner K; Serban C; Lighezan D; Fras Z; Moriarty PM; Muntner P; Goudev A; Ceska R; Nicholls SJ; Broncel M; Nikolic D; Pella D; Puri R; Rysz J; Wong ND; Bajnok L; Jones SR; Ray KK; Mikhailidis DP
Expert Opin Drug Saf; 2015 Jun; 14(6):935-55. PubMed ID: 25907232
[TBL] [Abstract][Full Text] [Related]
34. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
[TBL] [Abstract][Full Text] [Related]
35. Statin Toxicity.
Ward NC; Watts GF; Eckel RH
Circ Res; 2019 Jan; 124(2):328-350. PubMed ID: 30653440
[TBL] [Abstract][Full Text] [Related]
36. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
[TBL] [Abstract][Full Text] [Related]
37. New insights into managing symptoms during statin therapy.
Robinson JG
Prog Cardiovasc Dis; 2019; 62(5):390-394. PubMed ID: 31669768
[TBL] [Abstract][Full Text] [Related]
38. Unmet Patient Need in Statin Intolerance: the Clinical Characteristics and Management.
Harrison TN; Hsu JY; Rosenson RS; Levitan EB; Muntner P; Cheetham TC; Wei R; Scott RD; Reynolds K
Cardiovasc Drugs Ther; 2018 Feb; 32(1):29-36. PubMed ID: 29417422
[TBL] [Abstract][Full Text] [Related]
39. Statin intolerance: new data and further options for treatment.
Diaconu CC; Iorga RA; Furtunescu F; Katsiki N; Stoian AP; Rizzo M
Curr Opin Cardiol; 2021 Jul; 36(4):487-493. PubMed ID: 33929368
[TBL] [Abstract][Full Text] [Related]
40. Strategies to overcome statin intolerance.
Agouridis AP; Nair DR; Mikhailidis DP
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
